Obesity & OverweightGLP-BARI-VANNCT07901777
Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults With Obesity
An observational study of Obesity & Overweight, run by Yuzuncu Yil University at 1 site in Turkey (Türkiye).
Trial summary
This observational study will compare weight loss over two years in adults receiving GLP-1 receptor agonist medications with weight loss in adults who previously underwent laparoscopic sleeve gastrectomy, an operation that reduces the size of the stomach. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Obesity & Overweight
- What is being tested?
- GLP-1 Receptor Agonist Therapy and Laparoscopic Sleeve Gastrectomy
- Type of treatment
- Surgery or procedure
- How many people
- 200 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 15 Sep 2026to 15 Nov 2028
- How long will I take part?
- 24 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults aged 18 years or older receiving treatment for obesity or overweight at the Obesity Center of Van Training and Research Hospital, Türkiye. The prospective cohort will include consecutive eligible patients initiating GLP-1 receptor agonist therapy for weight management as part of routine clinical care. The retrospective cohort will include eligible patients who underwent primary laparoscopic sleeve gastrectomy for obesity at the same center between January 1, 2020, and January 1, 2026. Treatment decisions are made independently of study participation. The cohorts will be matched using propensity scores based on pretreatment demographic and clinical characteristics.
Who may be able to join
- GLP-1 Receptor Agonist Cohort:
- Age 18 years or older at treatment initiation.
- Initiation of a GLP-1 receptor agonist for obesity or overweight as part of routine clinical care.
- Available baseline height and body weight measurements.
- Willingness to attend at least one follow-up assessment.
- Ability to comply with the center's standard follow-up program.
Show all 13Show fewer
- Provision of written informed consent.
- Laparoscopic Sleeve Gastrectomy Cohort:
- Age 18 years or older at surgery.
- Primary laparoscopic sleeve gastrectomy for obesity performed at the study center between January 1, 2020, and January 1, 2026.
- Available preoperative height, body weight, and body mass index measurements.
- Available demographic and baseline clinical data.
- At least one documented postoperative body weight measurement. Availability of a 24-month weight measurement is preferred for the primary comparison.
Who cannot join
- Both Cohorts:
- Bariatric or metabolic surgery before the index treatment.
- Revisional bariatric surgery as the index treatment.
- Active malignancy or a serious systemic disease substantially affecting body weight.
- Pregnancy or breastfeeding at the index treatment.
- Uncontrolled endocrine disease that may cause weight loss.
Show all 16Show fewer
- Missing baseline height or body weight measurements.
- Recent participation in another intensive weight-loss program before the index treatment.
- Concurrent use of another anti-obesity treatment that could substantially affect study outcomes.
- Inability to reliably verify study data.
- GLP-1 Receptor Agonist Cohort:
- Short-term GLP-1 receptor agonist use for an indication other than weight management.
- Medication prescribed but never administered.
- Laparoscopic Sleeve Gastrectomy Cohort:
- Sleeve gastrectomy performed concurrently with another bariatric procedure.
- Sleeve gastrectomy performed for an indication other than primary obesity treatment.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site, 1 recruiting
- Recruiting
Yüzüncü Yıl University
Van
Mahir Coşkun, +905468843349, s.celik@yyu.edu.tr
About this study
Official title: Comparison of Two-Year Weight-Loss Effectiveness of GLP-1 Receptor Agonists and Laparoscopic Sleeve Gastrectomy in the Treatment of Obesity: An Ambispective Propensity Score-Matched Cohort Study
This observational study will compare weight loss over two years in adults receiving GLP-1 receptor agonist medications with weight loss in adults who previously underwent laparoscopic sleeve gastrectomy, an operation that reduces the size of the stomach.
Adults starting GLP-1 medications as part of their usual care will be followed for 24 months. Their results will be compared with existing medical records of adults who underwent sleeve gastrectomy at the same center. Treatment decisions will be made by patients and their treating clinicians as part of routine care, rather than assigned by the study.
The main outcome is the percentage of starting body weight lost at 24 months. The study will also assess weight changes at earlier visits, medication side effects, treatment continuation and reasons for stopping treatment, and changes in weight-related health conditions. The groups will be matched using baseline characteristics to make the comparison more balanced.
- Conditions
- Obesity & Overweight
- Being tested
- GLP-1 Receptor Agonist Therapy, Laparoscopic Sleeve Gastrectomy
- Keywords
- Obesity, Weight Loss, GLP-1 Receptor Agonists, Laparoscopic Sleeve Gastrectomy, Adverse Events
- Medical subject headings
- Obesity, Overweight, Weight Loss
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GLP-1 Receptor Agonist TherapyDrug
Also called Glucagon-Like Peptide-1 Receptor Agonist Therapy
GLP-1 receptor agonists, such as liraglutide or semaglutide, prescribed for weight management as part of routine clinical care. Medication selection, dose escalation, dose adjustment, and treatment discontinuation are determined by the treating clinician and are not assigned by the study protocol. Medication use, weight changes, treatment adherence, and adverse events will be recorded during 24 months of prospective follow-up.
Laparoscopic Sleeve GastrectomyProcedure or surgery
Primary laparoscopic sleeve gastrectomy performed for obesity as part of routine clinical care between January 1, 2020, and January 1, 2026. The procedure involves removing a large portion of the stomach to create a narrow, sleeve-shaped stomach. Existing medical records will be reviewed retrospectively to assess weight changes and surgical complications through 24 months after surgery.
| Study group | Role | What they receive |
|---|---|---|
| GLP-1 Receptor Agonist Cohort | Adults aged 18 years or older starting a GLP-1 receptor agonist, such as liraglutide or semaglutide, for weight management as part of routine clinical care. Participants will be followed prospectively for 24 months, with assessments at baseline and months 1, 3, 6, 12, and 24. Weight changes, medication use, treatment adherence, adverse events, and treatment discontinuation will be recorded. Medication selection and dosing will be determined by the treating clinician independently of study participation. Receives: Drug: GLP-1 Receptor Agonist Therapy | |
| Laparoscopic Sleeve Gastrectomy Cohort | Adults who underwent primary laparoscopic sleeve gastrectomy for obesity at the same center between January 1, 2020, and January 1, 2026, and were aged 18 years or older at surgery. Existing medical records will be reviewed retrospectively for baseline characteristics, postoperative weight measurements through 24 months, and surgical complications. This cohort will be matched with the GLP-1 receptor agonist cohort using propensity scores based on pretreatment characteristics. Surgery was performed as part of routine clinical care independently of this study. Receives: Procedure: Laparoscopic Sleeve Gastrectomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Total Body Weight Loss at 24 Months
Percentage of total body weight loss (%TWL), calculated as [(baseline body weight - body weight at 24 months) / baseline body weight] × 100. Baseline is the date of GLP-1 receptor agonist treatment initiation or sleeve gastrectomy. The outcome will be compared between the propensity score-matched treatment cohorts.
Measured: 24 months after GLP-1 receptor agonist treatment initiation or sleeve gastrectomy.
Secondary outcomes (20)
Percentage of Total Body Weight Loss at Earlier Follow-Up Visits
Percentage of total body weight loss (%TWL), calculated as [(baseline body weight - follow-up body weight) / baseline body weight] × 100, compared between the treatment cohorts.
Measured: At 1, 3, 6, and 12 months after treatment initiation.
Change in Body Weight
Change in body weight from baseline, measured in kilograms, compared between the treatment cohorts.
Measured: Baseline to months 1, 3, 6, 12, and 24.
Change in Body Mass Index
Change in body mass index (BMI) from baseline, calculated as body weight in kilograms divided by height in meters squared, compared between the treatment cohorts.
Measured: Baseline to months 1, 3, 6, 12, and 24.
Percentage of Participants Achieving at Least 5% Total Body Weight Loss
Percentage of participants losing at least 5% of their baseline body weight, compared between the treatment cohorts.
Measured: At months 1, 3, 6, 12, and 24.
Percentage of Participants Achieving at Least 10% Total Body Weight Loss
Percentage of participants losing at least 10% of their baseline body weight, compared between the treatment cohorts.
Measured: At months 1, 3, 6, 12, and 24.
Percentage of Participants Achieving at Least 15% Total Body Weight Loss
Percentage of participants losing at least 15% of their baseline body weight, compared between the treatment cohorts.
Measured: At months 1, 3, 6, 12, and 24.
Percentage of Participants Achieving at Least 20% Total Body Weight Loss
Percentage of participants losing at least 20% of their baseline body weight, compared between the treatment cohorts.
Measured: At months 1, 3, 6, 12, and 24.
Percentage of Participants Achieving at Least 25% Total Body Weight Loss
Percentage of participants losing at least 25% of their baseline body weight, compared between the treatment cohorts.
Measured: At months 1, 3, 6, 12, and 24.
Percentage of Participants Experiencing Any Adverse Event During GLP-1 Therapy
Percentage of participants in the GLP-1 receptor agonist cohort experiencing at least one adverse event. Event type, onset, severity, and suspected relationship to medication will be recorded.
Measured: From the first medication dose through 24 months.
Percentage of Participants Experiencing Gastrointestinal Adverse Events During GLP-1 Therapy
Percentage of participants in the GLP-1 receptor agonist cohort experiencing gastrointestinal adverse events, including nausea, vomiting, diarrhea, constipation, abdominal pain, or reflux/dyspepsia.
Measured: From the first medication dose through 24 months.
Percentage of Participants Experiencing Serious Adverse Events During GLP-1 Therapy
Percentage of participants in the GLP-1 receptor agonist cohort experiencing an adverse event resulting in death, a life-threatening condition, inpatient hospitalization or prolonged hospitalization, persistent or significant disability, a congenital anomaly, or another medically important event.
Measured: From the first medication dose through 24 months.
Percentage of Participants Requiring GLP-1 Dose Reduction Due to Adverse Events
Percentage of participants in the GLP-1 receptor agonist cohort whose medication dose is reduced because of an adverse event.
Measured: From treatment initiation through 24 months.
Percentage of Participants Permanently Discontinuing GLP-1 Therapy Due to Adverse Events
Percentage of participants in the GLP-1 receptor agonist cohort who permanently discontinue medication because of an adverse event.
Measured: From treatment initiation through 24 months.
Percentage of Participants Permanently Discontinuing GLP-1 Therapy for Any Reason
Percentage of participants in the GLP-1 receptor agonist cohort who permanently discontinue medication for any reason. Reasons for discontinuation will be recorded.
Measured: From treatment initiation through 24 months.
Duration of GLP-1 Treatment Persistence
Time in months from GLP-1 receptor agonist treatment initiation to permanent discontinuation. Participants without permanent discontinuation will be censored at their last known follow-up or the end of the 24-month observation period.
Measured: From treatment initiation through 24 months.
Improvement or Remission of Obesity-Related Comorbidities
Percentage of participants with improvement or remission of baseline obesity-related comorbidities, including type 2 diabetes, hypertension, and dyslipidemia, assessed separately for each condition using available clinical records, laboratory results, and medication changes.
Measured: At months 3, 6, 12, and 24.
Percentage of Participants With Emergency Department Visits
Percentage of participants with at least one emergency department visit during follow-up, assessed in each treatment cohort using available records.
Measured: From treatment initiation through 24 months.
Percentage of Participants With Hospital Admissions
Percentage of participants with at least one hospital admission during follow-up, excluding the index admission for sleeve gastrectomy, assessed in each treatment cohort using available records.
Measured: From treatment initiation through 24 months.
Percentage of Participants With Early Surgical Complications
Percentage of participants in the sleeve gastrectomy cohort experiencing a complication within 30 days after surgery, including bleeding, staple-line leak, or complications requiring reoperation. Complications will be graded using the Clavien-Dindo classification when sufficient information is available.
Measured: Within 30 days after sleeve gastrectomy.
Percentage of Participants With Late Surgical Complications
Percentage of participants in the sleeve gastrectomy cohort experiencing complications more than 30 days after surgery, including stenosis, gastroesophageal reflux, nutritional deficiencies, or complications requiring revision surgery, as documented in available records.
Measured: From postoperative day 31 through 24 months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Oct 2026
- Study start15 Sep 2026
- Primary completion15 Sep 2028 (estimated)
- Study completion15 Nov 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obesity & OverweightStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 200 participants (estimated)
- Target duration
- 24 Months
Sponsor and investigators
- Lead sponsor
- Yuzuncu Yil University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sebahattin Celik MD, Yuzuncu Yil University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07901777
- Sponsor's protocol ID
- GLP-BARI-VAN
- Acronym
- GLP-BARI-VAN
- Status last verified
- Oct 2026
- First submitted
- 22 Oct 2026
- Last updated
- 28 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Two-Year Weight-Loss Effectiveness of GLP-1 Receptor Agonists and Laparoscopic Sleeve Gastrectomy in the Treatment of Obesity: An Ambispective Propensity Score-Matched Cohort Study
- ClinicalTrials.gov ID
- NCT07901777
- Acronym / sponsor ID
- GLP-BARI-VAN / GLP-BARI-VAN
- Conditions
- Obesity & Overweight
- Keywords
- Obesity, Weight Loss, GLP-1 Receptor Agonists, Laparoscopic Sleeve Gastrectomy, Adverse Events
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Yuzuncu Yil UniversityUniversity, hospital or other
- Study start
- 15 Sep 2026 (actual)
- Primary completion
- 15 Sep 2028 (estimated)
- Study completion
- 15 Nov 2028 (estimated)
- First posted
- 28 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This observational study will compare weight loss over two years in adults receiving GLP-1 receptor agonist medications with weight loss in adults who previously underwent laparoscopic sleeve gastrectomy, an operation that reduces the size of the stomach.
Adults starting GLP-1 medications as part of their usual care will be followed for 24 months. Their results will be compared with existing medical records of adults who underwent sleeve gastrectomy at the same center. Treatment decisions will be made by patients and their treating clinicians as part of routine care, rather than assigned by the study.
The main outcome is the percentage of starting body weight lost at 24 months. The study will also assess weight changes at earlier visits, medication side effects, treatment continuation and reasons for stopping treatment, and changes in weight-related health conditions. The groups will be matched using baseline characteristics to make the comparison more balanced.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Target follow-up
- 24 Months
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| GLP-1 Receptor Agonist Cohort | – | Drug: GLP-1 Receptor Agonist TherapyAdults aged 18 years or older starting a GLP-1 receptor agonist, such as liraglutide or semaglutide, for weight management as part of routine clinical care. Participants will be followed prospectively for 24 months, with assessments at baseline and months 1, 3, 6, 12, and 24. Weight changes, medication use, treatment adherence, adverse events, and treatment discontinuation will be recorded. Medication selection and dosing will be determined by the treating clinician independently of study participation. |
| Laparoscopic Sleeve Gastrectomy Cohort | – | Procedure: Laparoscopic Sleeve GastrectomyAdults who underwent primary laparoscopic sleeve gastrectomy for obesity at the same center between January 1, 2020, and January 1, 2026, and were aged 18 years or older at surgery. Existing medical records will be reviewed retrospectively for baseline characteristics, postoperative weight measurements through 24 months, and surgical complications. This cohort will be matched with the GLP-1 receptor agonist cohort using propensity scores based on pretreatment characteristics. Surgery was performed as part of routine clinical care independently of this study. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adults aged 18 years or older receiving treatment for obesity or overweight at the Obesity Center of Van Training and Research Hospital, Türkiye. The prospective cohort will include consecutive eligible patients initiating GLP-1 receptor agonist therapy for weight management as part of routine clinical care. The retrospective cohort will include eligible patients who underwent primary laparoscopic sleeve gastrectomy for obesity at the same center between January 1, 2020, and January 1, 2026. Treatment decisions are made independently of study participation. The cohorts will be matched using propensity scores based on pretreatment demographic and clinical characteristics.
Key inclusion criteria (13 listed)
- Age 18 years or older at treatment initiation.
- Initiation of a GLP-1 receptor agonist for obesity or overweight as part of routine clinical care.
- Available baseline height and body weight measurements.
- Willingness to attend at least one follow-up assessment.
- Ability to comply with the center's standard follow-up program.
Key exclusion criteria (16 listed)
- Bariatric or metabolic surgery before the index treatment.
- Revisional bariatric surgery as the index treatment.
- Active malignancy or a serious systemic disease substantially affecting body weight.
- Pregnancy or breastfeeding at the index treatment.
- Uncontrolled endocrine disease that may cause weight loss.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GLP-1 Receptor Agonist TherapyAlso: Glucagon-Like Peptide-1 Receptor Agonist TherapyGLP-1 receptor agonists, such as liraglutide or semaglutide, prescribed for weight management as part of routine clinical care. Medication selection, dose escalation, dose adjustment, and treatment discontinuation are determined by the treating clinician and are not assigned by the study protocol. Medication use, weight changes, treatment adherence, and adverse events will be recorded during 24 months of prospective follow-up. | Drug | GLP-1 Receptor Agonist Cohort |
| Laparoscopic Sleeve GastrectomyPrimary laparoscopic sleeve gastrectomy performed for obesity as part of routine clinical care between January 1, 2020, and January 1, 2026. The procedure involves removing a large portion of the stomach to create a narrow, sleeve-shaped stomach. Existing medical records will be reviewed retrospectively to assess weight changes and surgical complications through 24 months after surgery. | Procedure or surgery | Laparoscopic Sleeve Gastrectomy Cohort |
Primary outcome
Percentage of Total Body Weight Loss at 24 Months
Time frame: 24 months after GLP-1 receptor agonist treatment initiation or sleeve gastrectomy.
Percentage of total body weight loss (%TWL), calculated as [(baseline body weight - body weight at 24 months) / baseline body weight] × 100. Baseline is the date of GLP-1 receptor agonist treatment initiation or sleeve gastrectomy. The outcome will be compared between the propensity score-matched treatment cohorts.
20 secondary outcomes
Percentage of Total Body Weight Loss at Earlier Follow-Up Visits
Time frame: At 1, 3, 6, and 12 months after treatment initiation.
Change in Body Weight
Time frame: Baseline to months 1, 3, 6, 12, and 24.
Change in Body Mass Index
Time frame: Baseline to months 1, 3, 6, 12, and 24.
Percentage of Participants Achieving at Least 5% Total Body Weight Loss
Time frame: At months 1, 3, 6, 12, and 24.
Percentage of Participants Achieving at Least 10% Total Body Weight Loss
Time frame: At months 1, 3, 6, 12, and 24.
Percentage of Participants Achieving at Least 15% Total Body Weight Loss
Time frame: At months 1, 3, 6, 12, and 24.
Percentage of Participants Achieving at Least 20% Total Body Weight Loss
Time frame: At months 1, 3, 6, 12, and 24.
Percentage of Participants Achieving at Least 25% Total Body Weight Loss
Time frame: At months 1, 3, 6, 12, and 24.
Percentage of Participants Experiencing Any Adverse Event During GLP-1 Therapy
Time frame: From the first medication dose through 24 months.
Percentage of Participants Experiencing Gastrointestinal Adverse Events During GLP-1 Therapy
Time frame: From the first medication dose through 24 months.
Percentage of Participants Experiencing Serious Adverse Events During GLP-1 Therapy
Time frame: From the first medication dose through 24 months.
Percentage of Participants Requiring GLP-1 Dose Reduction Due to Adverse Events
Time frame: From treatment initiation through 24 months.
Percentage of Participants Permanently Discontinuing GLP-1 Therapy Due to Adverse Events
Time frame: From treatment initiation through 24 months.
Percentage of Participants Permanently Discontinuing GLP-1 Therapy for Any Reason
Time frame: From treatment initiation through 24 months.
Duration of GLP-1 Treatment Persistence
Time frame: From treatment initiation through 24 months.
Improvement or Remission of Obesity-Related Comorbidities
Time frame: At months 3, 6, 12, and 24.
Percentage of Participants With Emergency Department Visits
Time frame: From treatment initiation through 24 months.
Percentage of Participants With Hospital Admissions
Time frame: From treatment initiation through 24 months.
Percentage of Participants With Early Surgical Complications
Time frame: Within 30 days after sleeve gastrectomy.
Percentage of Participants With Late Surgical Complications
Time frame: From postoperative day 31 through 24 months.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Obesity & Overweight
Not yet recruiting
Transcutaneous Auricular Vagus Nerve Stimulation Combined With Lifestyle Intervention for Visceral Fat Reduction in Adults With Overweight or Obesity
Overweight, Obesity
Not yet recruitingObservational study
Assessing the Impact of Perceptions of Unpredictability on Objective Measures of Food Consumption and Metabolism
Healthy Volunteer, Obestity
RecruitingPhase 1/2
HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Not yet recruitingPhase 3
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease
Not yet recruitingObservational study
A Natural History of Genetic and Environmental Predictors of Pubertal Timing Among Youth With Obesity
Obesity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Obesity & Overweight, run by Yuzuncu Yil University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 28 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sebahattin Çelik (+90 505 705 79 57, s.celik@yyu.edu.tr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Total Body Weight Loss at 24 Months (time frame: 24 months after GLP-1 receptor agonist treatment initiation or sleeve gastrectomy.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2026.